Latest Insider Transactions at Blueprint Medicines Corp (BPMC)
This section provides a real-time view of insider transactions for Blueprint Medicines Corp (BPMC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Blueprint Medicines Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Blueprint Medicines Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 07
2020
|
Mark Alan Goldberg |
BUY
Exercise of conversion of derivative security
|
Direct |
5,454
+37.69%
|
$103,626
$19.53 P/Share
|
|
Oct 07
2020
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
5,000
-3.41%
|
$495,000
$99.17 P/Share
|
|
Oct 07
2020
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.3%
|
$40,000
$8.8 P/Share
|
|
Oct 07
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
600
-5.67%
|
$60,000
$100.0 P/Share
|
|
Oct 07
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+5.36%
|
$4,800
$8.8 P/Share
|
|
Oct 06
2020
|
Marion Dorsch Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,600
-23.17%
|
$455,400
$99.0 P/Share
|
|
Oct 06
2020
|
Marion Dorsch Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,600
+18.81%
|
$170,200
$37.11 P/Share
|
|
Oct 01
2020
|
Fouad Namouni PRESIDENT, R & D |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+50.0%
|
-
|
|
Oct 01
2020
|
Nicholas Lydon |
SELL
Open market or private sale
|
Direct |
9,815
-7.43%
|
$902,980
$92.87 P/Share
|